Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 6/20 | 0.43 |
| ▸ | NTRK3 | Q16288 | 4/20 | 0.43 |
| ▸ | NTRK2 | Q16620 | 4/20 | 0.43 |
| ▸ | JAK2 | O60674 | 3/20 | 0.43 |
| ▸ | INSR | P06213 | 1/20 | 0.43 |
| ▸ | LYN | P07948 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | ROS1 | P08922 | 1/20 | 0.43 |
| ▸ | FGR | P09769 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.43 |
| ▸ | TIE1 | P35590 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17352968 | 0.83 | MAPT (0.46) | MAPTNTRK1JAK2 | |
| SCHEMBL17352966 | 0.83 | MAPT (0.46) | MAPTNTRK1JAK2 | |
| SCHEMBL21723176 | 0.81 | NTRK1 (0.47) | NTRK1NTRK3NTRK2JAK2INSR | |
| SCHEMBL17358803 | 0.81 | NTRK1 (0.47) | NTRK1NTRK3NTRK2JAK2INSR | |
| SCHEMBL17352919 | 0.80 | MAPT (0.48) | MAPTCHRNB2CHRNA4NTRK1JAK2 | |
| SCHEMBL21732185 | 0.78 | NTRK1 (0.51) | NTRK1NTRK3NTRK2JAK2INSR | |
| SCHEMBL21723138 | 0.76 | NTRK1 (0.52) | NTRK1NTRK3NTRK2JAK2INSR | |
| SCHEMBL21732105 | 0.76 | NTRK1 (0.52) | NTRK1NTRK3NTRK2JAK2INSR | |
| SCHEMBL21732256 | 0.75 | NTRK1 (0.47) | NTRK1NTRK3NTRK2JAK2INSR | |
| SCHEMBL17353202 | 0.75 | POLB (0.42) | MAPTCHRNB2CHRNA4NTRK1ROS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9782391-B2 | Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2017-10-10 | — | — | US | disclosed |
| US-20160279109-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-09-29 | — | — | US | disclosed |
| US-9394305-B2 | Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-07-19 | — | — | US | disclosed |
| US-20150368238-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160279109-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS | NTRK1, NTRK3, MUSK | MAPT 572/4885CHRNB2 717/4885CHRNA4 750/4885 |
| US-20150368238-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS | NTRK1, NTRK3, MUSK | MAPT 572/4885CHRNB2 717/4885CHRNA4 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.